The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics is progressing the development of its CD19-directed T cell engager, CLN-978, as a potential treatment for autoimmune diseases including rheumatoid arthritis, Sjögren’s disease, and systemic lupus erythematosus.
Chief Medical Officer Jeff Jones recently outlined the therapeutic focus in a video created together with the Global Healthy Living Foundation. The initiative positions CLN-978 within a growing field of targeted therapies aimed at immune system modulation for chronic conditions. Additional details can be found via Cullinan Therapeutics resources.
View post on X Loading...
Cullinan Therapeutics recently announced its Q2 2026 financial results and provided updates on key milestones for its T cell engager pipeline, including CLN-978, as detailed in company statements. The company has also engaged in industry events, supporting diversity by sponsoring LGBTQIA biotech professionals at OUTbio Boston. These efforts reflect Cullinan's ongoing activity in both clinical development and community engagement.